It was found that recombinant human endostatin combined with GP regimen did not improve the overall survival of patients with advanced NSCLC, but it did not exclude the bias caused by the small sample size of this study, and it was also affected by the later treatment effect of patients. The gene discussed is COL18A1; the disease is non-small cell lung carcinoma.